Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of ECSP024290ApublicationCriticalpatent/ECSP024290A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Composiciones farmacéuticas para administración oral, las cuales comprenden terbinafrina, y un método para administrar altas dosificaciones mientras que se minimizan los efectos asociados con, por ejemplo, una alta carga de dosificación, por ejemplo formulaciones de tabletas recubiertas o de múltiples partículas, tales como minitabletas en cápsulas.Pharmaceutical compositions for oral administration, which comprise terbinafrine, and a method for administering high dosages while minimizing the effects associated with, for example, a high dosage load, for example formulations of coated or multi-particle tablets, such as minitabletas in capsules
ECSP0242902001-12-042002-07-18
PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME
ECSP024290A
(en)
DERIVATIVES OF TRICYCLIC MACROLIDES, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, USE OF THEM TO PREPARE MEDICINES AND PROCEDURE FOR THEIR PREPARATION
PHARMACEUTICAL SALTS CONSTITUTED OF AN ACTIVE PHARMACEUTICAL SUBSTANCE AND AT LEAST A SWEETENER, MEDICATIONS CONTAINING THESE SALTS AND USE OF THESE SALTS FOR THE PREPARATION OF MEDICINES
USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
A PHARMACEUTICAL FORMULATION THAT INCLUDES AT LEAST A SELECTED COMPOSITE OF THE GROUP FORMED BY NON-BARBITURIC HYPNOTICS AND NON-BENZODIACEPINICS, AND MELATONIN
COMBINATION OF (A) AT LEAST A 2,5-DIHYDROBENCENOSULPHONIC DERIVATIVE, AS CALCIUM DOBEYLATE, ETHAMSYLATE AND PERSILATE, AND (B) AT LEAST A MODULATOR OF POTASSIUM CHANNELS, PHARMACEUTICAL COMPOSITION CONTAINING AND USE AS A MEDICATION IN PROFILA